Beckman Coulter Launches Groundbreaking Anti-TRBC2 Conjugated Antibody for Flow Cytometry
09 January 2024 | Tuesday | News
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with first-to-market concepts to help laboratories achieve goals faster and with greater accuracy. The company today announces it has developed the first commercially available anti-TRBC2 conjugated antibody for flow cytometry, providing greater clarity to clinical researchers in the identification of T-cell neoplasms in areas including cancer research.
Image Source : Public Domain
Traditional approaches to identify clonal T-cell expansion have been complex and challenging, relying on the assessment of abnormal antigen expression, which is often difficult to clearly identify and can overlap with reactive T-cell subsets. B-cells can offer a richer and more simplistic solution, with the detection of clonal B-cell expansion enabled by the staining of both surface kappa and lambda immunoglobulin light chains utilizing flow cytometry.
The TCR constant β chains 1 and 2, or TRBC1 and TRBC2, are randomly selected during T-cell development in the thymus and are mutually exclusive. Normal T-cell populations include a mix of the two, while clonal populations include only one. TRBC1 and TRBC2 staining using flow cytometry offers a low-cost, rapid, and specific T-cell clonality test. Both can be conjugated to any dye in the Beckman Coulter Life Sciences portfolio through Custom Design Services either as a standalone conjugated antibody, or part of liquid or dry custom panels.
“Beckman Coulter Life Sciences has been committed to T-cell research for more than 25 years as we launched our Beta Mark TCR Vβ Repertoire Kit, and we’ve aggressively continued to innovate and raise the bar with solutions for this pioneering method to help labs ensure greater accuracy with fewer touchpoints,” said Pietro Lopriore, Vice President and General Manager of the Flow Cytometry Business Unit. “This advancement creates a revolutionary step forward in reducing complexities while providing clearer results in the important area of T-cell cancer research.”
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
